Format

Send to

Choose Destination
Haematologica. 2014 Oct;99(10):1582-90. doi: 10.3324/haematol.2014.106880. Epub 2014 Aug 1.

Impact of the International Prognostic Scoring System cytogenetic risk groups on the outcome of patients with primary myelodysplastic syndromes undergoing allogeneic stem cell transplantation from human leukocyte antigen-identical siblings: a retrospective analysis of the European Society for Blood and Marrow Transplantation-Chronic Malignancies Working Party.

Author information

1
Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico and University of Milan, Italy francesco.onida@unimi.it.
2
University Medical Center, Leiden, the Netherlands.
3
Chronic Malignancy WP Registry, Leiden, the Netherlands.
4
Radboud University - Nijmegen Medical Centre, Nijmegen, the Netherlands.
5
University Hospital of Leuven, Belgium.
6
University Hospital, Department of Bone Marrow Transplantation, Essen, Germany.
7
Hospital Clinic, Barcelona, Spain.
8
Policlinico San Matteo, Pavia, Italy.
9
Helsinki University Central Hospital, Finland.
10
University Medical Centre Utrecht, the Netherlands.
11
Hospital de la Princesa, Madrid, Spain.
12
Hospital Santa Creu I Sant Pau, Barcelona, Spain.
13
Department of Medicine-Hematology, Oncology, Freiburg, Germany.
14
University Hospital Eppendorf, Hamburg, Germany.

Abstract

Acquired chromosomal abnormalities are important prognostic factors in patients with myelodysplastic syndromes treated with supportive care and with disease-modifying therapeutic interventions, including allogeneic hematopoietic stem cell transplantation. To assess the prognostic impact of cytogenetic characteristics after hematopoietic stem cell transplantation accurately, we investigated a homogeneous group of 523 patients with primary myelodysplastic syndromes who have received stem cells from human leukocyte antigen-identical siblings. Overall survival at five years from transplantation in good, intermediate, and poor cytogenetic risk groups according to the International Prognostic Scoring System was 48%, 45% and 30%, respectively (P<0.01). Both the disease status (complete remission vs. not in complete remission) and the morphological classification at transplant in the untreated patients were significantly associated with probability of overall survival and relapse-free survival (P<0.01). The cytogenetic risk groups have no prognostic impact in untreated patients with refractory anemia ± ringed sideroblasts (P=0.90). However, combining the good and intermediate cytogenetic risk groups and comparing them to the poor-risk group showed within the other three disease-status-at-transplant groups a hazard ratio of 1.86 (95%CI: 1.41-2.45). In conclusion, this study shows that, in a large series of patients with primary myelodysplastic syndromes, poor-risk cytogenetics as defined by the standard International Prognostic Scoring System is associated with a relatively poor survival after allogeneic stem cell transplantation from human leukocyte antigen-identical siblings except in patients who are transplanted in refractory anemia/refractory anemia with ringed sideroblasts stage before progression to higher myelodysplastic syndrome stages.

PMID:
25085359
PMCID:
PMC4181254
DOI:
10.3324/haematol.2014.106880
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for HighWire Icon for PubMed Central
Loading ...
Support Center